Bioequivalence study of new disodium salt formulation of CH 1504 [Chelsea Therapeutics]
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2007
At a glance
- Drugs CH 1504 (Primary)
- Indications Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Chelsea Therapeutics
- 10 Sep 2007 Status changed from recruiting to completed.
- 10 Sep 2007 Results reported in a media release.
- 13 Aug 2007 New trial record.